A Phase 3 interventional study of Dexmedetomidine and Magnesium sulfate in Cough, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-06-11.
Sponsored by Al-Azhar University · Phase 3, Interventional, and Prevention
The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.
427 studies on the registry are indexed under Cough; 67 are open to participants now.
This study's planned enrollment of 300 is above the median of 80 across 319 interventional studies indexed under Cough.
Browse Cough studies →Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive 0.5 μg/kg dexmedetomidine in 10 ml normal saline 10 min before the end of surgery.
Drug: Dexmedetomidine
Patients will receive 30 mg/kg IV magnesium sulfate 50% in 10 ml normal saline 10 min before the end of surgery.
Drug: Magnesium sulfate
Patients will receive lidocaine 1.5 mg/kg lidocaine in 10 ml normal saline 10 min before the end of surgery.
Drug: Lidocaine
Patients will receive 10 ml normal saline 10 min before the end of surgery.
Drug: normal saline
Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
Also known as: dex
Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
Also known as: MgSO4
Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
Patients will receive 10 ml normal saline 10 min before the end of surgery.
Cough suppression as regard number and severity.
Coughing severity will be classified using the 3 point scale described by Minogue et al.: 1 = mild, single cough, 2 = moderate (lasting for \<5 seconds) cough, and severe (lasting for \>5 seconds) cough.
Time frame: at 0 and 10,20,30,40 minutes after endotracheal extubation.
Intraoperative heart rate (HR).
Changes in Intraoperative heart rate. change in heart rate per minute (HR/minute) will be all measured from the patient's arrival at the operating room to the end of surgery.
Time frame: at 15-minutes interval.
Intraoperative mean arterial blood pressure (MAP).
Changes in Intraoperative mean arterial blood pressure (MAP). change in mean arterial blood pressure (MAP) in mmHg will be all measured from the patient's arrival at the operating room to the end of surgery.
Time frame: at 15-minutes interval.
Intraoperative arterial oxygen saturation (Spo2).
Changes in Intraoperative arterial oxygen saturation (Spo2%). change in arterial oxygen saturation (Spo2%). be all measured from the patient's arrival at the operating room to the end of surgery.
Time frame: at 15-minutes interval.
Sedation score.
Sedation score will be recorded using the Ramsay sedation score (Ramsay et al., 1974).
Time frame: at 0,10,20,30, and 40 minutes after tracheal extubation.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Magnesium Sulfate · Lidocaine